Ulcerative Colitis

The cause of these diseases is poorly understood and no current management strategy is effective.

Current treatments do not provide a cure, and all produce significant unwanted side effects.

The disease usually recurs, with relapse rates of up to 80 per cent within the first year post-remission.

On this basis, the most effective management strategy is to devise improved maintenance therapy and treatment regimens which prolong the periods of remission without unwanted side effects.

Previous animal studies indicated NV-52 appears to be suited as a maintenance therapy to prevent relapse of disease.

Novogen is an Australian biopharmaceutical company specialising in the development of therapeutics based on the isoflavonoid chemical structure.

The Company is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases and phenoxodiol, its lead anti-cancer agent is currently in advanced Phase II clinical trialing with its US listed subsidiary Marshall Edwards Inc.

.

More information on the Novogen Group can be found at http://www.novogen.com and http://www.marshalledwardsinc.com .

Under U.S.

law, an investigational drug cannot be marketed until it has be...

Read more...